We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The commission has already signed a contract with AstraZeneca for up to 400 million doses of its vaccine and is in ongoing discussions with other companies for supply deals. Read More
In a letter to Gilead Sciences, almost a dozen state treasurers accused the company of seeking “unreasonable profits” from its antiviral COVID-19 treatment remdesivir, demanding that it lower the price. Read More
Eli Lilly has entered into a global partnership with Amgen to increase supply capacity for Eli Lilly’s neutralizing antibodies as a treatment for COVID-19 patients. Read More
Co-developers Pfizer and BioNTech are preparing for a global roll-out of the vaccine as soon as it receives an Emergency Use Authorization or approval. Read More
Two plans — one from Operation Warp Speed and one from the Centers for Disease Control and Prevention — for distributing a COVID-19 vaccine are short on crucial details and leaves much of the distribution to state and local authorities. Read More
Novavax President and CEO Stanley C. Erck said the company anticipates starting phase 3 efficacy trials around the world “in the coming weeks.” Read More
Novavax has expanded its COVID-19 vaccine manufacturing agreement with the Serum Institute of India to produce more than 2 billion doses of the vaccine annually. Read More
Gilead Sciences has announced that it will spend $21 billion to acquire New Jersey drugmaker Immunomedics as part of its ongoing expansion into immune-oncology treatments. Read More